What is the recommended approach for diagnosing and managing inflammatory bowel disease in primary care?

Inflammatory Bowel Disease in Primary Care

Initial Assessment and Diagnosis

Primary care physicians should immediately obtain a full blood count, CRP, albumin, stool cultures to exclude infection (including C. difficile), and faecal calprotectin when IBD is suspected, followed by urgent gastroenterology referral for colonoscopy with histology to confirm diagnosis. 1

Key Clinical Indicators for Suspicion

• Persistent diarrhea (especially bloody), abdominal pain, weight loss, and extraintestinal manifestations warrant immediate workup 1
• Faecal calprotectin has excellent sensitivity for IBD but poor specificity—infections and drugs commonly cause false positives 1
• The diagnosis ultimately requires endoscopic visualization and histological confirmation; biomarkers alone are insufficient 1

Diagnostic Workup Algorithm

Step 1: Laboratory and Stool Testing

• Full blood panel including CBC, CRP, albumin 1
• Stool culture for bacterial pathogens including Salmonella 2
• C. difficile testing (glutamate dehydrogenase antigen and toxin A/B, or nucleic acid amplification) 2
• Faecal calprotectin or lactoferrin 1
• If travel history suggests endemic exposure: stool examination for ova, cysts, parasites, and Strongyloides serology 2

Step 2: Urgent Gastroenterology Referral

• Colonoscopy with segmental biopsies remains the gold standard for diagnosis 1, 2
• For acute severe colitis presentation: unprepared flexible sigmoidoscopy during acute phase, followed by planned colonoscopy for disease extent assessment 1
• Endoscopic appearance may underestimate true extent, particularly in quiescent disease—segmental biopsies are essential 1

Critical Pitfall: Infection Exclusion

All patients with suspected IBD flare must have C. difficile excluded, as it is associated with increased colectomy rates and poorer outcomes, particularly in ulcerative colitis. 2 In UC patients, C. difficile positivity rates reach 13.6% in some series, compared to lower rates in Crohn's disease 2. Do not routinely perform PCR interrogation of feces beyond standard testing, as this detects bacteria of unclear clinical significance even in healthy controls 2.

Role of Primary Care in Ongoing Management

When to Refer vs. Co-manage

Primary care physicians should collaborate closely with gastroenterology for all IBD patients, as comprehensive care requires specialist input for disease monitoring and treatment adjustments, while primary care manages routine health maintenance and recognizes early complications. 3, 4

• Early recognition and timely referral by primary care physicians is crucial for preventing disease progression 4
• Most IBD care could be delivered in primary care with continued specialist collaboration, though current data shows primary care physician IBD knowledge and comfort levels are suboptimal 3
• Patients on advanced therapies (immunomodulators like azathioprine/methotrexate or biologics) require special counseling regarding adverse effects, infection risk, cancer risk, and pregnancy considerations 5

Monitoring for Complications

Primary care physicians must maintain high vigilance for:

• Steroid-resistant disease: If a patient fails to respond to corticosteroids, test for CMV reactivation, as it is associated with reduced therapy efficacy and increased colectomy rates 2
• Opportunistic infections: Corticosteroid and thiopurine exposure increase CMV reactivation risk, though tissue damage is rare 2
• Disease extent changes: Up to 50% of patients with proctitis or proctosigmoiditis develop more extensive disease over time 1

Health Maintenance Priorities

• Comprehensive preventive care including vaccination status (particularly before immunosuppression), cancer surveillance, and bone health monitoring 5
• Mental health screening for anxiety, depression, and fatigue, which significantly complicate disease management 6
• Nutritional assessment to prevent sarcopenia and malnutrition 6

Disease Classification and Prognosis

Disease extent determines prognosis: extensive colitis carries a 19% 10-year colectomy rate versus 8% for left-sided colitis and 5% for proctitis 1. Extensive colitis also confers the highest colorectal cancer risk 1. Classification should always reflect maximal disease extent, as inflammation can regress over time but the highest risk category persists 1.

Emerging Treatment Paradigms

Newer treatment strategies incorporate earlier use of biologic therapy, often combined with immunomodulators, to alter the natural disease course 5. While these advanced therapies are costly, they are likely cost-effective given improved remission rates and quality of life 5. Early therapeutic intervention with complete disease control may allow dose reduction or treatment withdrawal in maintenance phase, reducing side effects and costs 4.